Is Broadcom Stock a Millionaire Maker?
Broadcom (Nasdaq: AVGO) stock has gone up more than 64%…
Buy
61
MLSS Quote, Financials, Valuation and Earnings
Last price:
$0.95
Seasonality move
:
9.68%
Day range:
$0.99 - $1.07
52-week range:
$0.58 - $1.39
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
9.09x
P/B ratio:
13.25x
Volume:
50.6K
Avg. volume:
61.8K
1-year change:
51.68%
Market cap:
$77.3M
Revenue:
$8.6M
EPS (TTM):
-$0.07
Analysts' Opinion
-
Consensus RatingMilestone Scientific has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $2.13, Milestone Scientific has an estimated upside of 115.54% from its current price of $0.99.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.25 representing 100% downside risk from its current price of $0.99.
Fair Value
-
According to the consensus of 1 analyst, Milestone Scientific has 115.54% upside to fair value with a price target of $2.13 per share.
MLSS vs. S&P 500
-
Over the past 5 trading days, Milestone Scientific has overperformed the S&P 500 by 0.02% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Milestone Scientific does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Milestone Scientific revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Milestone Scientific reported revenues of $2.5M.
Earnings Growth
-
Milestone Scientific has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Milestone Scientific reported earnings per share of -$0.02.
Enterprise value:
74M
EV / Invested capital:
--
Price / LTM sales:
9.09x
EV / EBIT:
--
EV / Revenue:
8.58x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-25.26x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$6.4M
Return On Assets:
-40.87%
Net Income Margin (TTM):
-52.01%
Return On Equity:
-61.33%
Return On Invested Capital:
-61.33%
Operating Margin:
-58.44%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $8.8M | $9.8M | $8.6M | $2.3M | $2M | |
| Gross Profit | $4.9M | $6.8M | $6.4M | $1.5M | $1.5M | |
| Operating Income | -$8.8M | -$7.1M | -$6.8M | -$2M | -$2M | |
| EBITDA | -$8.7M | -$7M | -$6.6M | -$1.9M | -$2M | |
| Diluted EPS | -$0.12 | -$0.10 | -$0.07 | -$0.03 | -$0.03 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $18.6M | $18.9M | $13M | $10.8M | $9.3M | |
| Total Assets | $19.6M | $19.8M | $13.7M | $11.4M | $9.8M | |
| Current Liabilities | $2.9M | $3.1M | $3.3M | $3.1M | $3.7M | |
| Total Liabilities | $3.5M | $3.6M | $3.7M | $3.4M | $4M | |
| Total Equity | $16.1M | $16.2M | $10M | $8M | $5.8M | |
| Total Debt | $276.2K | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$6M | -$5.3M | -$2.9M | -$1.2M | -$1.5M | |
| Cash From Investing | -$8.5K | -$3M | $3M | -$514.3K | -$3.5K | |
| Cash From Financing | -$8.5K | $2.6M | $233.8K | $2.6M | -$2.5K | |
| Free Cash Flow | -$6M | -$5.3M | -$2.9M | -$1.2M | -$1.5M | |
MLSS
Sector
Market Cap
$77.3M
$35.1M
Price % of 52-Week High
70.8%
44.56%
Dividend Yield
0%
0%
Shareholder Yield
-3.91%
-0.74%
1-Year Price Total Return
51.68%
-40.62%
Beta (5-Year)
0.934
0.662
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.99
200-day SMA
Buy
Level
$0.96
Bollinger Bands (100)
Sell
Level
0.88 - 1.16
Chaikin Money Flow
Buy
Level
13.6M
20-day SMA
Buy
Level
$0.94
Relative Strength Index (RSI14)
Buy
Level
51.59
ADX Line
Buy
Level
12.21
Williams %R
Neutral
Level
-47.9151
50-day SMA
Buy
Level
$0.96
MACD (12, 26)
Buy
Level
0.01
25-day Aroon Oscillator
Buy
Level
72
On Balance Volume
Neutral
Level
66.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-7.68)
Sell
CA Score
(Annual)
Level (-2.3156)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (4.6064)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (7)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Milestone Scientific Inc is a biomedical technology company. The company is engaged in pioneering proprietary, technological systems and solutions for the medical and dental markets. The company develops, manufactures, markets, and sells the computer-controlled system for the improved and painless delivery of local anesthetics. The system is marketed in dentistry under the trademark CompuDent and in medicine under the trademark CompuMed. The Company conducts its business through two reportable segments: Dental and Medical.
Stock Forecast FAQ
In the current month, MLSS has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MLSS average analyst price target in the past 3 months is $2.13.
-
Where Will Milestone Scientific Stock Be In 1 Year?
According to analysts, the consensus estimate is that Milestone Scientific share price will rise to $2.13 per share over the next 12 months.
-
What Do Analysts Say About Milestone Scientific?
Analysts are divided on their view about Milestone Scientific share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Milestone Scientific is a Sell and believe this share price will drop from its current level to $1.25.
-
What Is Milestone Scientific's Price Target?
The price target for Milestone Scientific over the next 1-year time period is forecast to be $2.13 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MLSS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Milestone Scientific is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of MLSS?
You can purchase shares of Milestone Scientific via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Milestone Scientific shares.
-
What Is The Milestone Scientific Share Price Today?
Milestone Scientific was last trading at $0.95 per share. This represents the most recent stock quote for Milestone Scientific. Yesterday, Milestone Scientific closed at $0.99 per share.
-
How To Buy Milestone Scientific Stock Online?
In order to purchase Milestone Scientific stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire The Best Stock to Buy in a Bad Market?
Berkshire Hathaway (NYSE:BRK.A, BRK.B) has historically been one of the…
Is Shopify Stock Still a Buy in 2025 or Has Growth Peaked?
The big picture trends in e‑commerce sales are clearly in…
Stock Ideas
Buy
71
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
63
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Buy
60
RGC alert for May 6
Regencell Bioscience Holdings [RGC] is up 73.72% over the past day.
Buy
63
SKX alert for May 6
Skechers USA [SKX] is down 0.07% over the past day.
Sell
20
PTCT alert for May 6
PTC Therapeutics [PTCT] is down 11% over the past day.
